EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis
Oncology Research and Treatment · 2024
DOI: 10.1159/000541494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research and Treatment, 2024. Verfasst von Wenjuan Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China. Hauptthemen laut MEDLINE: Brain Neoplasms, Adenocarcinoma of Lung, ErbB Receptors, Lung Neoplasms. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
Introduction
This study aimed to retrospectively analyse the response and prognosis factors for patients with lung adenocarcinoma exhibiting brain metastasis and epidermal growth factor receptor (EGFR) mutations, who were treated with a combination of EGFR-tyrosine kinase inhibitor (TKI) and brain radiotherapy (RT).
Methods
Clinicopathological data of patients with lung adenocarcinoma were collected from January 2021 to January 2024 at the First Affiliated Hospital of Hebei North University. Statistical analysis was performed using SPSS version 26.0, with significance set at p < 0.05.
Results
A total of 105 patients were included. The overall survival (OS) rates at 1, 2, and 3 years were 82.9%, 61.2%, and 33.7%, respectively. The progression-free survival 1 (PFS1) rates at 1, 2, and 3 years were 62.7%, 36.6%, and 22.1%, respectively. The progression-free survival 2 (PFS2) rates at 1, 2, and 3 years were 80.8%, 54.6%, and 31.4%, respectively. The median OS, PFS1, and PFS2 were 29.8, 18.0, and 28.1 months, respectively. Cox multivariate analysis identified gene mutation status and brain radiation dose as independent prognostic factors for OS. For PFS1, gene mutation status, brain radiation dose, and initial treatment response were independent prognostic factors. Clinical stage, gene mutation status, brain radiation dose, and initial treatment response were independent prognostic factors for PFS2.
Conclusion
The combination of TKIs and brain RT is effective for patients with lung adenocarcinoma with EGFR mutations and brain metastases. Patients with exon 19 Del or exon 21 L858R mutations and brain radiation doses ≥40 Gy exhibit longer OS, PFS1, and PFS2. Additionally, complete remission + partial remission is associated with extended PFS1 and PFS2, while patients in stage IVA show longer PFS2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
- Department of Pharmacy, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
- School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
- Department of Respiratory, The First Hospital of Jilin University, Changchun, China.
Zitieren
APA
Yu, W., Xing, Y., Song, X., Li, T., & Zhang, M. (2024). EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis. Oncology Research and Treatment. https://doi.org/10.1159/000541494
Vancouver
Yu W, Xing Y, Song X, Li T, Zhang M. EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis. Oncology Research and Treatment. 2024. doi:10.1159/000541494
BibTeX
@article{Yu2024,
author = {Yu, Wenjuan and Xing, Yuan and Song, Xiao and Li, Tian and Zhang, Mi},
title = {EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis},
journal = {Oncology Research and Treatment},
year = {2024},
doi = {10.1159/000541494}
}
EUVIMED